| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2016-11-01 |
复牌提示：
2016-11-01 08:37:33 停牌，复牌日期 2016-11-02 00:00:01
|
| 2016-11-01 |
详情>>
内部人交易：
Frazier Healthcare V, LP等共交易6笔
|
| 2016-08-09 |
详情>>
股本变动：
变动后总股本1882.12万股
|
| 2016-04-28 |
股东大会：
将于2016-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the three director nominees named in the proxy statement accompanying this notice to serve as Class III directors for a three-year term expiring at the annual meeting of stockholders in 2019 and until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as Tobira Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2015-06-04 |
股东大会：
将于2015-07-09召开股东大会
会议内容 ▼▲
- (1)To elect the three director nominees named in the proxy statement accompanying this notice to serve as Class II directors for a three-year term expiring at the annual meeting of stockholders in 2018 and until their successors are duly elected and qualified.
(2)To ratify the appointment of Ernst & Young LLP as Tobira Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
(3)To approve amendments to and the material terms of our 2013 Equity Compensation Plan, including an increase in the number of shares reserved for issuance thereunder by 1,200,000 and, among other amendments, increases in or imposition of certain share limits under such plan.
(4)To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2015-03-24 |
股东大会：
将于2015-05-04召开股东大会
会议内容 ▼▲
- 1. To approve the issuance of Regado common stock pursuant to (i) the Agreement and Plan of Merger and Reorganization, dated as of January 14, 2015, as amended on January 23, 2015, by and among Regado, Tobira Therapeutics, Inc., Landmark Merger Sub Inc. and Brent Ahrens, as the Tobira stockholders’ agent, a copy of which is attached as Annex A to the accompanying proxy statement, and (ii) the financing commitment letter with Tobira and certain stockholders of Tobira, pursuant to which Regado will sell, and such stockholders have agreed to buy, immediately following the closing of the Merger, $22 million of shares of Regado common stock, which amount may be increased to up to $40 million by mutual agreement of Regado and Tobira, a copy of which is attached as Annex B to the accompanying proxy statement.
2. To approve the amended and restated certificate of incorporation of Regado to effect a reverse stock split of Regado common stock, at a ratio of one new share for every nine shares outstanding, in the form attached as Annex C to the accompanying proxy statement.
3. To approve the amendment to the amended and restated certificate of incorporation of Regado to change the name “Regado Biosciences, Inc.” to “Tobira Therapeutics, Inc.” in the form attached as Annex D to the accompanying proxy statement.
4. To approve an adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Regado Proposal Nos. 1, 2 and 3.
|
| 2014-05-05 |
股东大会：
将于2014-06-12召开股东大会
会议内容 ▼▲
- 1. To elect three director nominees to serve as Class I directors for a three-year term expiring at the annual meeting of stockholders in 2017;
2. To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2014;
3. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement;
4. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers;
5. To consider any other matters that may properly come before the Annual Meeting.
|